The IGR-CaP1 Xenograft Model Recapitulates Mixed Osteolytic/Blastic Bone Lesions Observed in Metastatic Prostate Cancer

被引:31
作者
Al Nakouzi, Nader [1 ,2 ]
Bawa, Olivia [2 ,3 ]
Le Pape, Alain [4 ,5 ]
Lerondel, Stephanie [4 ]
Gaudin, Catherine [1 ,2 ]
Opolon, Paule [2 ,3 ]
Gonin, Patrick [2 ]
Fizazi, Karim [1 ,2 ,6 ]
Chauchereau, Anne [1 ,2 ]
机构
[1] Inst Gustave Roussy, INSERM U981, Prostate Canc Grp, F-94805 Villejuif, France
[2] Univ Paris Sud 11, Paris, France
[3] Inst Gustave Roussy, IRCIV, Expt Pathol Unit, Villejuif, France
[4] CNRS, UPS44 TAAM CIPA, F-45071 Orleans, France
[5] INSERM EA U1100 6305, Tours, France
[6] Inst Gustave Roussy, Dept Canc Med, Villejuif, France
来源
NEOPLASIA | 2012年 / 14卷 / 05期
关键词
CELL-LINE; TUMOR; MARKERS; MECHANISMS; EXPRESSION; TURNOVER; GROWTH; LOCALIZATION; INVOLVEMENT; PROGRESSION;
D O I
10.1593/neo.12308
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bone metastases have a devastating impact on quality of life and bone pain in patients with prostate cancer and decrease survival. Animal models are important tools in investigating the pathogenesis of the disease and in developing treatment strategies for bone metastases, but few animal models recapitulate spontaneous clinical bone metastatic spread. In the present study, IGR-CaP1, a new cell line derived from primary prostate cancer, was stably transduced with a luciferase-expressing viral vector to monitor tumor growth in mice using bioluminescence imaging. The IGR-CaP1 tumors grew when subcutaneously injected or when orthotopically implanted, reconstituted the prostate adenocarcinoma with glandular acini-like structures, and could disseminate to the liver and lung. Bone lesions were detected using bioluminescence imaging after direct intratibial or intracardiac injections. Anatomic bone structure assessed using high-resolution computed tomographic scans showed both lytic and osteoblastic lesions. Technetium Tc 99m methylene diphosphonate micro single-photon emission computed tomography confirmed the mixed nature of the lesions and the intensive bone remodeling. We also identified an expression signature for responsiveness of IGR-CaP1 cells to the bone microenvironment, namely expression of CXCR4, MMP-9, Runx2, osteopontin, osteoprotegerin, ADAMTS14, FGFBP2, and HBB. The IGR-CaP1 cell line is a unique model derived from a primary tumor, which can reconstitute human prostate adenocarcinoma in animals and generate experimental bone metastases, providing a novel means for understanding the mechanisms of bone metastasis progression and allowing preclinical testing of new therapies. Neoplasia (2012) 14, 376-387
引用
收藏
页码:376 / +
页数:13
相关论文
共 53 条
  • [1] Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions
    Akech, J.
    Wixted, J. J.
    Bedard, K.
    van der Deen, M.
    Hussain, S.
    Guise, T. A.
    van Wijnen, A. J.
    Stein, J. L.
    Languino, L. R.
    Altieri, D. C.
    Pratap, J.
    Keller, E.
    Stein, G. S.
    Lian, J. B.
    [J]. ONCOGENE, 2010, 29 (06) : 811 - 821
  • [2] CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy
    Bettencourt, MC
    Bauer, JJ
    Sesterhenn, IA
    Connelly, RR
    Moul, JW
    [J]. JOURNAL OF UROLOGY, 1998, 160 (02) : 459 - 465
  • [3] CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment
    Burger, JA
    Kipps, TJ
    [J]. BLOOD, 2006, 107 (05) : 1761 - 1767
  • [4] Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples
    Cawthorn, T. R.
    Amir, E.
    Broom, R.
    Freedman, O.
    Gianfelice, D.
    Barth, D.
    Wang, D.
    Holen, I.
    Done, S. J.
    Clemons, M.
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 2009, 26 (08) : 935 - 943
  • [5] Breast cancer progression: insights into multifaceted matrix metalloproteinases
    Chabottaux, Vincent
    Noel, Agnes
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 2007, 24 (08) : 647 - 656
  • [6] Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process
    Chandran, Uma R.
    Ma, Changqing
    Dhir, Rajiv
    Bisceglia, Michelle
    Lyons-Weiler, Maureen
    Liang, Wenjing
    Michalopoulos, George
    Becich, Michael
    Monzon, Federico A.
    [J]. BMC CANCER, 2007, 7 (1)
  • [7] Experimental models for the development of new medical treatments in prostate cancer
    Chauchereau, Anne
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S200 - S214
  • [8] Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer
    Chauchereau, Anne
    Al Nakouzi, Nader
    Gaudin, Catherine
    Le Moulec, Sylvestre
    Compagno, Daniel
    Auger, Nathalie
    Benard, Jean
    Opolon, Paule
    Rozet, Francois
    Validire, Pierre
    Fromont, Gaelle
    Fizazi, Karim
    [J]. EXPERIMENTAL CELL RESEARCH, 2011, 317 (03) : 262 - 275
  • [9] Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation
    Chen, Gaoping
    Sircar, Kanishka
    Aprikian, Armen
    Potti, Anil
    Goltzman, David
    Rabbani, Shafaat A.
    [J]. CANCER, 2006, 107 (02) : 289 - 298
  • [10] Metastatic prostate carcinoma to bone - Clinical and pathologic features associated with cancer-specific survival
    Cheville, JC
    Tindall, D
    Boelter, C
    Jenkins, R
    Lohse, CM
    Pankratz, VS
    Sebo, TJ
    Davis, B
    Blute, ML
    [J]. CANCER, 2002, 95 (05) : 1028 - 1036